Published in

SAGE Publications, Journal of Onco-Nephrology, 3(6), p. 97-106, 2022

DOI: 10.1177/23993693221098444

Links

Tools

Export citation

Search in Google Scholar

Nephrological management of renal cell carcinoma (RCC) patients: A narrative review

Journal article published in 2022 by Marta Pirovano ORCID, Laura Cosmai ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Renal Cell Carcinoma (RCC) is the most frequent malignancy encountered in general nephrology practice; when kidney disease develops in the setting of RCC, it may limit long-term outcomes, patients often dying of a non-cancer-related complication of kidney disease. There is a reciprocal relationship between renal cancer and kidney; chronic kidney disease can increase the risk of developing kidney cancer, and patients with RCC often experience renal impairment owing to pre-existing chronic kidney disease (CKD), hypertension (HTN), diabetes mellitus (DM), and/or other medically challenging comorbidities, or risk factors for CKD. Nephrologists should be involved in all aspects of RCC patients’ care, from pre-nephrectomy evaluation, to management of post-nephrectomy CKD, through the recognition and management of anticancer drugs-related kidney toxicity. This collaborative approach to RCC care will further improve the clinical outcomes of kidney cancer patients.